Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.38 |
| ▸ | CFTR | P13569 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23298020 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL29909642 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL29543281 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL25924960 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL23342642 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL23298019 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL23298057 | 1.00 | RIPK1 (0.38) | RIPK1CFTRELANEMEN1KMT2A | |
| Lithium Ion SCHEMBL31678048 | 0.88 | RIPK1 (0.37) | RIPK1CFTRELANEMEN1KMT2A | |
| Lithium Ion SCHEMBL30997317 | 0.88 | RIPK1 (0.37) | RIPK1CFTRELANEMEN1KMT2A | |
| SCHEMBL23298034 | 0.84 | L3MBTL1 (0.42) | MEN1KMT2APOLBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | RIPK1 801/4885CFTR 707/4885ELANE 1737/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | RIPK1 1490/4885CFTR 201/4885ELANE 1632/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | RIPK1 819/4885CFTR 316/4885ELANE 1926/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | RIPK1 826/4885CFTR 1070/4885ELANE 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.